Oliver Rosen
About
Oliver Rosen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology.
According to data from OpenAlex, Oliver Rosen has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Gastroenterology. Recurrent topics in Oliver Rosen's work include Colorectal Cancer Treatments and Studies (4 papers), Gastrointestinal Tumor Research and Treatment (4 papers) and Virus-based gene therapy research (3 papers). Oliver Rosen is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Gastrointestinal Tumor Research and Treatment (4 papers) and Virus-based gene therapy research (3 papers). Oliver Rosen collaborates with scholars based in United States, Canada and Germany. Oliver Rosen's co-authors include Herbert I. Hurwitz, Jing Yi, Will Ince, William Novotny, Somnath Sarkar, Fairooz F. Kabbinavar, H. Radtke, Gero Massenkeil, Andreas Thiel and Renate Arnold and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Oliver Rosen
18 papers receiving 1.2k citations
Peers
Oliver Rosen
Young Wha Koh South Korea
Andy Sherrod United States
Giovannella Palmieri Italy
Chueh‐Chuan Yen Taiwan
C. Calandri Italy
Xiaopei Zhu United States
Xiaonan Hong China
Lorenza Landi Italy
Idris Tolgay Ocal United States
Citations per year, relative to Oliver Rosen Oliver Rosen (= 1×)
peers
Young Wha Koh
Countries citing papers authored by Oliver Rosen
Since
Specialization
Citations
This map shows the geographic impact of Oliver Rosen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Rosen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Rosen more than expected).
Fields of papers citing papers by Oliver Rosen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Oliver Rosen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Rosen. The network helps show where Oliver Rosen may publish in the future.
Co-authorship network of co-authors of Oliver Rosen
This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Rosen. A scholar is included among the top collaborators of Oliver Rosen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Rosen. Oliver Rosen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rosen, Lee S., Christian H. Ottensmeier, M. Hawkins, et al.. (2025). Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration. PubMed. 8(4). 263–275.
2.
Naing, Aung, Danny N. Khalil, Oliver Rosen, et al.. (2024). First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. Journal for ImmunoTherapy of Cancer. 12(10). e010016–e010016.
3.
O’Reilly, Eileen M., Mark H. O’Hara, George A. Fisher, et al.. (2023). 765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial. SHILAP Revista de lepidopterología. A860–A860.
4.
Jimeno, Antonio, Joaquina Baranda, Monica Mita, et al.. (2021). Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.. Journal of Clinical Oncology. 39(15_suppl). 2536–2536.
5.
Jankú, Filip, Albiruni R. Abdul Razak, Ping Chi, et al.. (2020). Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology. 38(28). 3294–3303.
6.
George, Suzanne, Michael C. Heinrich, Albiruni Ryan Abdul Razak, et al.. (2018). Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. Journal of Clinical Oncology. 36(15_suppl). 11511–11511.
7.
Jankú, Filip, Michael C. Heinrich, Albiruni R. Abdul Razak, et al.. (2018). Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST). Cancer Research. 78(13_Supplement). CT029–CT029.
8.
Lin, Nancy U., Tatiana M. Prowell, Antoinette R. Tan, et al.. (2017). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group. Journal of Clinical Oncology. 35(33). 3760–3773.
9.
Jankú, Filip, Albiruni Ryan Abdul Razak, Michael S. Gordon, et al.. (2017). Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2515–2515.
10.
Groot, John de, Suzanne George, Albiruni R. Abdul Razak, et al.. (2017). ACTR-02. DCC-2618, A NOVEL pan-KIT AND PDGFRa KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi1–vi1.
11.
Cortes, Jörge E., Moshe Talpaz, Hedy Smith, et al.. (2016). Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 102(3). 519–528.
12.
Hurwitz, Herbert I., Pamela S. Douglas, John P. Middleton, et al.. (2013). Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies. The Oncologist. 18(3). 273–280.
13.
Bagri, Anil, Leanne Berry, Bert Gunter, et al.. (2010). Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy. Clinical Cancer Research. 16(15). 3887–3900.
14.
Hurwitz, Herbert I., Jing Yi, Will Ince, William Novotny, & Oliver Rosen. (2009). The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer. The Oncologist. 14(1). 22–28.
15.
Kabbinavar, Fairooz F., Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, & Oliver Rosen. (2008). Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials. Journal of Clinical Oncology. 27(2). 199–205.
16.
Alexander, Tobias, Andreas Thiel, Oliver Rosen, et al.. (2008). Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 113(1). 214–223.
17.
Massenkeil, Gero, Marion Nagy, Philipp le Coutre, et al.. (2004). Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. The Hematology Journal. 5(5). 395–402.
18.
Vanhoefer, U., Mitra Tewes, Federico Rojo, et al.. (2003). Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor. Journal of Clinical Oncology. 22(1). 175–184.
19.
Rosen, Oliver, Andreas Thiel, Gero Massenkeil, et al.. (2000). Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Research & Therapy. 2(4). 327–36.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Young Wha Koh Breakdown of academic impact, for papers by Andy Sherrod Breakdown of academic impact, for papers by Giovannella Palmieri Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by C. Calandri Breakdown of academic impact, for papers by Xiaopei Zhu Breakdown of academic impact, for papers by Xiaonan Hong Breakdown of academic impact, for papers by Lorenza Landi Breakdown of academic impact, for papers by Idris Tolgay Ocal